Prime Medicine (PRME) Change in Cash (2021 - 2026)
Prime Medicine posted quarterly Change in Cash of $1.1 million for Q1 2026, up 101.19% year-on-year from $533835.8 in Q1 2025, and up 112.84% on a QoQ basis from -$8.4 million in Q4 2025.
Prime Medicine (PRME) has 6 years of Change in Cash data on file, last reported at $1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Cash rose 101.19% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$28.1 million (down 1537.11% YoY), and the FY2025 full-year result was -$119.8 million, down 184.69% from the prior year.
- Change in Cash for Q1 2026 stood at $1.1 million, up from -$8.4 million in the prior quarter.
- Across five years, Change in Cash topped out at $139.7 million in Q4 2022 and bottomed at -$90.6 million in Q1 2025.
- The 5-year median for Change in Cash is -$12.9 million (2023), against an average of -$7.1 million.
- The widest annual swing landed in 2022, when Change in Cash soared 6691.46%; it then tumbled 272.28% in 2025.
- A 5-year view of Change in Cash shows it stood at $139.7 million in 2022, then plunged by 101.71% to -$2.4 million in 2023, then surged by 2804.36% to $64.5 million in 2024, then tumbled by 112.97% to -$8.4 million in 2025, then jumped by 112.84% to $1.1 million in 2026.
- The last three Change in Cash figures came in at $1.1 million (Q1 2026), -$8.4 million (Q4 2025), and $17.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 623.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 417.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -153.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Prime Medicine | 601.24 Mn | 601.24 Mn | - | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | -8.36 Mn |
| Sep 30, 2025 | 17.59 Mn |
| Jun 30, 2025 | -38.44 Mn |
| Mar 31, 2025 | -90.60 Mn |
| Dec 31, 2024 | 64.50 Mn |
| Sep 30, 2024 | 62.94 Mn |
| Jun 30, 2024 | -38.56 Mn |
| Mar 31, 2024 | 52.59 Mn |
| Dec 31, 2023 | -2.39 Mn |
| Sep 30, 2023 | -76.62 Mn |
| Jun 30, 2023 | -12.89 Mn |
| Mar 31, 2023 | -54.16 Mn |
| Dec 31, 2022 | 139.67 Mn |
| Sep 30, 2022 | -44.29 Mn |
| Jun 30, 2022 | -71.64 Mn |
| Mar 31, 2022 | -21.17 Mn |
| Dec 31, 2021 | -2.12 Mn |